{"name":"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","slug":"trius-therapeutics-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"TR-701 FA tablets","genericName":"TR-701 FA tablets","slug":"tr-701-fa-tablets","indication":"Other","status":"phase_1"},{"name":"TR-701 di-sodium phosphate salt","genericName":"TR-701 di-sodium phosphate salt","slug":"tr-701-di-sodium-phosphate-salt","indication":"Other","status":"phase_1"},{"name":"TR701 FA","genericName":"TR701 FA","slug":"tr701-fa","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TR-701 FA","genericName":"TR-701 FA","slug":"tr-701-fa","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"}]}],"pipeline":[{"name":"TR-701 FA tablets","genericName":"TR-701 FA tablets","slug":"tr-701-fa-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TR-701 FA","genericName":"TR-701 FA","slug":"tr-701-fa","phase":"phase_3","mechanism":"TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)","Community-acquired bacterial pneumonia (CABP)"],"catalyst":""},{"name":"TR-701 di-sodium phosphate salt","genericName":"TR-701 di-sodium phosphate salt","slug":"tr-701-di-sodium-phosphate-salt","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TR701 FA","genericName":"TR701 FA","slug":"tr701-fa","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":2,"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}